About EuroStemCell

Wendy Bickmore is Director of the MRC Human Genetics Unit, part of the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh.  After an undergraduate degree in Biochemistry at Oxford, she obtained her PhD at Edinburgh University.  During postdoctoral training, she became fascinated by the structure and organization of chromosomes in the nucleus and as an independent fellow of the Lister Institute of Preventive Medicine (1991-1996) she went on to show that different human chromosomes have preferred positions in the nucleus, related to their gene content. As an MRC group leader she then investigated how individual genes are organized and packaged in the nucleus and how they move in the cell cycle and during development. Current research in Wendy Bickmore’s laboratory focuses on how the spatial organization of the nucleus influences genome function in development and disease. Wendy is an EMBO member and a Fellow of the Royal Society of Edinburgh and of the Academy of Medical Sciences. She is an editor on many journals including PLoS Genetics and Cell and is the President-Elect of the Genetics Society.

Hans Clevers is Principal Investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research (KNAW) and the Princess Máxima Center for pediatric oncology and also Professor of Molecular Genetics at the UMC Utrecht and Utrecht University, and Oncode Investigator.

Clevers discovered how the Wnt signaling pathway dictates cell fate decisions during animal embryogenesis by controlling gene expression. Looking beyond embryogenesis, he unveiled the role of Wnt signaling in colon cancer and in its physiological counterpart, the self-renewing gut epithelium. Combining these insights, he described the generic stem cell marker gene Lgr5, which has identified multiple novel adult stem cell types. Against prevailing views, these stem cells could be expanded indefinitely as organoids: mini-organs that recapitulate healthy or diseased human tissue in a dish. Organoids are rapidly gaining ground as research tools in a wide range of scientific disciplines including basic developmental and cell biology, infectiology, toxicology and research on hereditary diseases and cancer.

Centre for Genomic Regulation, Barcelona

Thomas Graf is Coordinator of the Differentiation and Cancer Programme at the Center for Genomic Regulation and an ICREA professor in Barcelona, Spain. His lab is interested in the role of transcription factors in hematopoiesis and leukemia, and how these regulators can induce trans-differentiation. Is blood cell differentiation a strictly hierarchical process or does more than one pathway exist for the formation of a given cell type? More specifically, how does a single transcription factor, C/EBPa, reprogram B-lymphocytes to become functional macrophages? During this process, what epigenetic changes are required to turn thousands of genes off and on, making a 'cell within a cell'? What are the common principles during induced transdifferentiation? Answering some of these questions will enhance our understanding of the connection between differentiation and cancer. They will also help designing new protocols for the controlled reprogramming of differentiated cells that might be useful for cell replacement therapies.



Read an interview with Thomas Graf by Monya Baker of Nature Stem Cell Reports (requires subscription): Cellular Identity and Transdifferentiation

Usher Institute for Population Health Sciences and Informatics

Sarah Chan is a recently-appointed Chancellor’s Fellow at the Usher Institute for Population Health Sciences and Informatics, University of Edinburgh. She was educated at the University of Melbourne, Australia, where she completed degrees in biological science and in law, and spent a number of years as a researcher in a molecular biology laboratory before moving to work in the area of science policy and stem cell ethics. In 2005 Sarah took up a Research Fellowship in Bioethics and Law at the Centre for Social Ethics and Policy, University of Manchester, where she also completed a MA in Health Care Ethics and Law and a PhD in Bioethics. From 2009 to 2015 she was Deputy Director of the Institute for Science, Ethics and Innovation, University of Manchester. Her research interests and publications cover areas including the ethics of gene therapy and genetic information, enhancement, research ethics, stem cells, animal ethics, transhumanism, and the ethics of science and innovation.

Freddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences.

Faculty of Medicine, Lund University, Sweden

Göran Hermerén has been Professor of Medical Ethics at the Faculty of Medicine, Lund University, Sweden, since 1991. He has also held the position of Professor of Philosophy, Lund University, since 1975 and he was Professor of Philosophy of Science and Humanities, Umeå University from 1970-75. He is co-ordinator of the EU-funded research project Europriorities and is involved in several other EU-funded projects. He has published and edited books on research ethics as well as papers on ethical problems (mainly medical ethics) in international periodicals. Current research and teaching interests include ethical aspects of gene testing and stem cell research.

The Tajbakhsh group focuses on identifying and characterising skeletal muscle stem cells. They use a genetic approach to examine how skeletal muscle stem cells are born, and how they acquire their identity. They also investigate the cell division mechanisms that govern self-renewal and differentiation during embryonic development and in the adult. They are able to isolate skeletal muscle stem cells for potential therapies using engineered fluorescent markers.

Leiden University Medical Centre

Christine Mummery is Professor and chair of Developmental Biology at Leiden University Medical Centre. She pioneered studies on cardiomyocytes from human embryonic stem cells and was among the first to inject them in mouse heart after myocardial infarction Present interests are on using stem cell derived cardiomyocytes and vascular cells as disease models, for drug discovery.  In 2007, she was a joint Harvard Stem Cell Institute/Radcliffe fellow.  

She presently serves on several Ethical Councils, Scientific Advisory and Editorial Boards and has written a popular book on stem cells. She is also on the board of ISSCR, president of the International Society of Differentiation and an elected  member of the Royal Netherlands Academy of Science.

Read our interview with Christine Mummery: A physicist's take on stem cell biology.

Andras is member of the Stem Cell Committee of the Hungarian Academy of Sciences, the Medical Research Council Committee on Human Reproduction and board member of the Hungarian Biotechnology Association. The Molecular Animal Biotechnology Laboratory of the Szent Istvan University, Hungary was established with his appointment as full professor. Furthermore, he is an invited professor at the Veterinary Faculty of Utrecht University, the Netherlands. He has an MBA-level degree in management and years of international experience in project and team management, and creation of industrial spin-offs via his role as co-founder and director of BioTalentum Ltd (www.biotalentum.eu). Prof. Dinnyes is member and advisor in several professional associations and society, and works as editor for the World Journal of Stem Cells and as Senior Editorial Board for the American Journal of Stem Cells. He was rewarded with the Gábor Dennis Innovation Award, Hungary in 2013.

Philip Newsome is Professor of Experimental Hepatology and Clinical Director of the Birmingham University Stem Cell Centre. He is an Area Lead (Liver Regeneration) in the NIHR Birmingham Liver Biomedical Research Unit.

Philip has published over major research papers in scientific journals as well as reviews and book chapters in the fields of stem cell biology and liver disease. He has received major grants from NIHR, European Union, Wellcome Trust, UKSCF, BBSRC and the Medical Research Council.

He is an enthusiastic communicator on the theme of translational stem cell work and non-alcoholic fatty liver disease and gives frequent talks to various groups at both the local and national level. Philip frequently contributes to both the local and national media and continues to advise the BBC on stem cell-related stories.

Center for Regenerative Medicine University of Modena and Reggio Emilia

Professor De Luca, and his principal collaborator Graziella Pellegrini, have been involved in epithelial stem cell biology aimed at clinical application in regenerative medicine for over 20 years. Beside his work on the use of human epidermal stem cell cultures in life-saving treatment of massive full-thickness burns and in repigmentation of stable vitiligo and piebaldism, he established human limbal stem cell culture aimed at corneal regeneration in patients with severe limbal stem cell deficiency. This treatment leads to recovery of vision in patients with poor alternative options for therapy. Michele De Luca is currently coordinating the first (successful) ex-vivo epithelial stem cell-mediated gene therapy clinical trial for the gene therapy of junctional epidermolysis bullosa, a serious genetic skin disease. He is also studying molecular mechanisms regulating self-renewal, proliferative potential and clonal evolution of epithelial stem cells.

Read an interview with Michele De Luca.

IRIBHM, Université Libre de Bruxelles

Professor Blanpain is a researcher of the Belgian FNRS and group leader at IRIBHM, Université Libre de Bruxelles (ULB), Belgium, and is a PI in the current EuroStemCell (H2020) project. His lab is interested in understanding the role of epithelial stem cells during development, homeostasis, cancer initiation and growth.

Stem cells (SCs) have the unique capacity to self-renew and to differentiate into the cell lineages that constitute their tissue of origin. SCs are found in many adult tissues and are critical for maintaining tissue homeostasis and for regenerating damaged tissue after injuries. We are using genetic lineage tracing experiments in mice to determine how stratified epithelia are formed during embryonic development and are maintained thereafter during tissue homeostasis. We are studying how adult SCs sense and respond to DNA damage in their natural niche.

Two epithelial skin cancers are frequent in human populations: the squamous cell carcinoma and the basal cell carcinoma. The identification of the cells at the origin of these two frequent human cancers remains elusive. We are using mouse genetics to identify cells at the origin of these two frequent cancers and developed new approach to understand the molecular changes that occurred from the first oncogenic event to the development of invasive cancers.

Paolo De Coppi is a Consultant Paediatric Surgeon at Great Ormond Street Hospital (GOSH), and Reader and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health in London.

He has been an Honorary Professor at the Katholieke Universiteit Leuven, Belgium, since 2013, an Adjunct Assistant Professor at the Wake Forest Institute for Regenerative Medicine, Wake Forest University in Winston-Salem, North Carolina, since 2009 and an Honorary Assistant Professor in Paediatric Surgery at the University of Padua, Italy, since 2005. He co-ordinates the EU Horizon2020 funded stem cell research consortium - INTENS which aims to aims to make a functional reconstructed bowel for people with Short Bowel Syndrome.